WO1999041368A3 - Optimization of immunomodulatory properties of genetic vaccines - Google Patents

Optimization of immunomodulatory properties of genetic vaccines Download PDF

Info

Publication number
WO1999041368A3
WO1999041368A3 PCT/US1999/003020 US9903020W WO9941368A3 WO 1999041368 A3 WO1999041368 A3 WO 1999041368A3 US 9903020 W US9903020 W US 9903020W WO 9941368 A3 WO9941368 A3 WO 9941368A3
Authority
WO
WIPO (PCT)
Prior art keywords
optimization
immunomodulatory properties
genetic vaccines
molecules
immune response
Prior art date
Application number
PCT/US1999/003020
Other languages
French (fr)
Other versions
WO1999041368A2 (en
Inventor
Juha Punnonen
Willem P C Stemmer
Robert Gerald Whalen
Russell Howard
Original Assignee
Maxygen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Inc filed Critical Maxygen Inc
Priority to CA002320960A priority Critical patent/CA2320960A1/en
Priority to MXPA00007889A priority patent/MXPA00007889A/en
Priority to AU26741/99A priority patent/AU2674199A/en
Priority to EP99906948A priority patent/EP1053312A2/en
Priority to JP2000531549A priority patent/JP2002507392A/en
Publication of WO1999041368A2 publication Critical patent/WO1999041368A2/en
Publication of WO1999041368A3 publication Critical patent/WO1999041368A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

This invention provides methods for obtaining molecules that can modulate an immune response, and immunomodulatory molecules obtained using the methods. The molecules find use, for example, in the tailoring of an immune response induced by a genetic vaccine for a desired purpose.
PCT/US1999/003020 1998-02-11 1999-02-10 Optimization of immunomodulatory properties of genetic vaccines WO1999041368A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002320960A CA2320960A1 (en) 1998-02-11 1999-02-10 Optimization of immunomodulatory properties of genetic vaccines
MXPA00007889A MXPA00007889A (en) 1998-02-11 1999-02-10 Optimization of immunomodulatory properties of genetic vaccines.
AU26741/99A AU2674199A (en) 1998-02-11 1999-02-10 Optimization of immunomodulatory properties of genetic vaccines
EP99906948A EP1053312A2 (en) 1998-02-11 1999-02-10 Optimization of immunomodulatory properties of genetic vaccines
JP2000531549A JP2002507392A (en) 1998-02-11 1999-02-10 Optimization of immunomodulatory properties of gene vaccines

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2176998A 1998-02-11 1998-02-11
US7429498P 1998-02-11 1998-02-11
US60/074,294 1998-02-11
US09/021,769 1998-02-11

Publications (2)

Publication Number Publication Date
WO1999041368A2 WO1999041368A2 (en) 1999-08-19
WO1999041368A3 true WO1999041368A3 (en) 1999-12-16

Family

ID=26695070

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/US1999/003020 WO1999041368A2 (en) 1998-02-11 1999-02-10 Optimization of immunomodulatory properties of genetic vaccines
PCT/US1999/003023 WO1999041402A2 (en) 1998-02-11 1999-02-10 Targeting of genetic vaccine vectors
PCT/US1999/003022 WO1999041369A2 (en) 1998-02-11 1999-02-10 Genetic vaccine vector engineering

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/US1999/003023 WO1999041402A2 (en) 1998-02-11 1999-02-10 Targeting of genetic vaccine vectors
PCT/US1999/003022 WO1999041369A2 (en) 1998-02-11 1999-02-10 Genetic vaccine vector engineering

Country Status (6)

Country Link
EP (3) EP1053343A2 (en)
JP (3) JP2002507392A (en)
AU (3) AU3291099A (en)
CA (3) CA2320431A1 (en)
MX (3) MXPA00007891A (en)
WO (3) WO1999041368A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821957B2 (en) 1997-05-20 2004-11-23 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
US9512382B2 (en) 2009-10-16 2016-12-06 Bunge Global Innovation, Llc Oil degumming methods

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US6399383B1 (en) 1997-10-28 2002-06-04 Maxygen, Inc. Human papilloma virus vectors
WO1999023107A1 (en) 1997-10-31 1999-05-14 Maxygen, Incorporated Modification of virus tropism and host range by viral genome shuffling
US6908757B1 (en) 1998-03-26 2005-06-21 The Procter & Gamble Company Serine protease variants having amino acid deletions and substitutions
KR20010052894A (en) 1998-06-17 2001-06-25 맥시겐, 인크. Method for producing polynucleotides with desired properties
US6605430B1 (en) 1998-08-12 2003-08-12 Maxygen, Inc. DNA shuffling of monooxygenase genes for production of industrial chemicals
JP2002526107A (en) 1998-10-07 2002-08-20 マキシジェン， インコーポレイテッド DNA shuffling to generate nucleic acids for mycotoxin detoxification
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
AU1619400A (en) 1998-11-10 2000-05-29 Maxygen, Inc. Modified adp-glucose pyrophosphorylase for improvement and optimization of plantphenotypes
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
EP1108783A3 (en) 1999-01-19 2001-09-05 Maxygen, Inc. Oligonucleotide-mediated nucleic acid recombination
EP1073710A4 (en) * 1999-02-04 2007-12-19 Verenium Corp Non-stochastic generation of genetic vaccines and enzymes
IL144657A0 (en) 1999-02-11 2002-06-30 Maxygen Inc High throughput mass spectrometry
US6531316B1 (en) 1999-03-05 2003-03-11 Maxyag, Inc. Encryption of traits using split gene sequences and engineered genetic elements
CZ2002171A3 (en) 1999-07-22 2002-06-12 The Procter & Gamble Company Proteinase conjugate, cleansing agent and preparation for personal hygiene
US6946128B1 (en) 1999-07-22 2005-09-20 The Procter & Gamble Company Protease conjugates having sterically protected epitope regions
BR0012660A (en) 1999-07-22 2002-04-09 Procter & Gamble Protease variant of subtilisin type; cleaning composition; and personal care composition
CN1373802A (en) 1999-07-22 2002-10-09 宝洁公司 Subtilisin protease variants having amino acid deletions and substitutions in defined epitope regions
US6686515B1 (en) 1999-11-23 2004-02-03 Maxygen, Inc. Homologous recombination in plants
US7115712B1 (en) * 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
WO2001059071A2 (en) 2000-02-09 2001-08-16 Genvec, Inc. Methods of preparing and using a viral vector library
AU2001259957B2 (en) * 2000-05-26 2006-06-15 Savine Therapeutics Pty Ltd Synthetic peptides and uses therefore
AUPQ776100A0 (en) 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
AU2001272978A1 (en) 2000-06-23 2002-01-08 Maxygen, Inc. Novel co-stimulatory molecules
AU2001268716A1 (en) 2000-06-23 2002-01-08 Maxygen, Inc. Novel chimeric promoters
AU2001273009A1 (en) * 2000-06-26 2002-01-08 Maxygen, Inc. Methods and compositions for developing spore display systems for medicinal and industrial applications
US6858422B2 (en) 2000-07-13 2005-02-22 Codexis, Inc. Lipase genes
AU2004260931B9 (en) 2003-04-29 2012-01-19 E.I. Du Pont De Nemours And Company Novel glyphosate-N-acetyltransferase (GAT) genes
DE10060959A1 (en) * 2000-12-06 2002-06-20 Aventis Res & Tech Gmbh & Co Processes for isolating and identifying effectors
AU2002314712C1 (en) * 2001-02-02 2008-10-02 Novici Biotech Llc A method of increasing complementarity in a heteroduplex polynucleotide
WO2002094992A2 (en) 2001-05-18 2002-11-28 Rigel Pharmaceuticals, Incorporated Directed evolution of protein in mammalian cells
AU2002326437A1 (en) * 2001-07-19 2003-03-03 Icogen Corporation Methods for the identification of peptidyl compounds interacting with extracellular target molecules
EP2301553A1 (en) * 2001-11-21 2011-03-30 The Board Of Trustees Of The Leland Stanford Junior University Polynucleotide therapy
CA2481479C (en) 2002-02-26 2012-12-11 Maxygen, Inc. Novel flavivirus antigens
ES2564570T3 (en) 2002-03-01 2016-03-23 Codexis Mayflower Holdings, Llc Methods, systems and software for the identification of functional biomolecules
JP4851687B2 (en) 2002-03-09 2012-01-11 マキシジェン， インコーポレイテッド Crossover optimization for directed evolution
US7226771B2 (en) 2002-04-19 2007-06-05 Diversa Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
EP2298871A1 (en) 2002-04-19 2011-03-23 Verenium Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
CA2494798A1 (en) 2002-08-06 2005-01-13 Verdia, Inc. Ap1 amine oxidase variants
AU2003297155B2 (en) 2002-12-16 2010-03-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant vaccine viruses expressing IL-15 and methods of using the same
EP3023498B1 (en) 2003-03-06 2018-11-28 BASF Enzymes LLC Amylases, nucleic acids encoding them and methods for making and using them
EP3299465A1 (en) 2003-03-07 2018-03-28 DSM IP Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
EP1613733B1 (en) 2003-04-04 2015-06-03 BASF Enzymes LLC Pectate lyases, nucleic acids encoding them and methods for making and using them
NZ570709A (en) * 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
JP2007529993A (en) 2003-07-02 2007-11-01 シンジェンタ パーティシペーションズ アーゲー Glucanases, nucleic acids encoding them and methods for making and using them
WO2005021714A2 (en) 2003-08-11 2005-03-10 Diversa Corporation Laccases, nucleic acids encoding them and methods for making and using them
CA2734624A1 (en) 2004-06-09 2005-12-29 Pioneer Hi-Bred International, Inc. Plastid transit peptides
EP2468853B1 (en) 2004-06-16 2015-04-01 DSM IP Assets B.V. Method for enzymatic decolorization of pheophytin
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
EP1869174B1 (en) 2005-03-10 2015-02-18 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
EP1861506B1 (en) 2005-03-15 2015-04-15 BP Corporation North America Inc. Cellulases, nucleic acids encoding them and methods for making and using them
US8715988B2 (en) 2005-03-28 2014-05-06 California Institute Of Technology Alkane oxidation by modified hydroxylases
WO2007092314A2 (en) 2006-02-02 2007-08-16 Verenium Corporation Esterases and related nucleic acids and methods
NZ595501A (en) 2006-02-10 2013-05-31 Verenium Corp Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
US8043839B2 (en) 2006-02-14 2011-10-25 Verenium Corporation Xylanases, nucleic acids encoding them and methods for making and using them
CN101437954B (en) 2006-03-07 2015-09-09 嘉吉公司 The nucleic acid of zymohexase and coding zymohexase and their preparation and application
CN101443446B (en) 2006-03-07 2013-08-21 维莱尼姆公司 Aldolases, nucleic acids encoding them and methods for making and using them
MX369001B (en) 2006-08-04 2019-10-24 Basf Enzymes Llc Glucanases, nucleic acids encoding them and methods for making and using them.
PT2397486E (en) 2006-09-21 2015-03-23 Basf Enzymes Llc Phytases, nucleic acids encoding them and methods for making and using them
MX2009003034A (en) 2006-09-21 2009-11-18 Verenium Corp Phospholipases, nucleic acids encoding them and methods for making and using them.
ES2620288T3 (en) 2006-12-21 2017-06-28 Basf Enzymes Llc Amylases and glucoamylases, nucleic acids that encode them and methods to form and use them
BRPI0807132A2 (en) 2007-01-30 2018-12-04 Syngenta Participations Ag enzymes for the treatment of lignocellulosics, nucleic acids encoding them, and methods and use thereof
EP2205744B1 (en) 2007-10-03 2015-01-14 BP Corporation North America Inc. Xylanases, nucleic acids encoding them and methods for making and using them
ES2399088T3 (en) 2007-11-01 2013-03-25 Perseid Therapeutics Llc Immunosuppressive polypeptides and nucleic acids
JP5563990B2 (en) 2008-01-03 2014-07-30 ヴェレニウム コーポレイション Transferases and oxidoreductases, nucleic acids encoding them and methods for making and using them
US8541220B2 (en) 2008-01-03 2013-09-24 Verenium Corporation Isomerases, nucleic acids encoding them and methods for making and using them
EP3115459A3 (en) 2008-05-23 2017-04-26 E. I. du Pont de Nemours and Company Novel dgat genes for increased seed storage lipid production and altered fatty acid profiles in oilseed plants
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
NZ592070A (en) 2008-09-26 2012-07-27 Tocagen Inc Gene therapy vectors and humanized yeast cytosine deaminase triple mutant
CN106011159A (en) 2009-05-21 2016-10-12 巴斯夫酶有限责任公司 Phytases, nucleic acids encoding them and methods for making and using them
CA2770854A1 (en) 2009-08-20 2011-02-24 Pioneer Hi-Bred International, Inc. Functional expression of shuffled yeast nitrate transporter (ynt1) in maize to improve nitrate uptake under low nitrate environment
UA109884C2 (en) 2009-10-16 2015-10-26 A POLYPEPTIDE THAT HAS THE ACTIVITY OF THE PHOSPHATIDYLINOSYTOL-SPECIFIC PHOSPHOLIPASE C, NUCLEIC ACID, AND METHOD OF METHOD
CA2786001A1 (en) 2009-12-31 2011-07-07 Pioneer Hi-Bred International, Inc. Engineering plant resistance to diseases caused by pathogens
US9187762B2 (en) 2010-08-13 2015-11-17 Pioneer Hi-Bred International, Inc. Compositions and methods comprising sequences having hydroxyphenylpyruvate dioxygenase (HPPD) activity
US20150184173A1 (en) 2012-05-04 2015-07-02 E I Du Pont De Nemours And Company Compositions and methods comprising sequences having meganuclease activity
US20140289906A1 (en) 2013-03-14 2014-09-25 Pioneer Hi-Bred International, Inc. Compositions Having Dicamba Decarboxylase Activity and Methods of Use
US20160040149A1 (en) 2013-03-14 2016-02-11 Pioneer Hi-Bred International Inc. Compositions Having Dicamba Decarboxylase Activity and Methods of Use
EP2971000A4 (en) 2013-03-15 2016-11-23 Pioneer Hi Bred Int Phi-4 polypeptides and methods for their use
US10006045B2 (en) 2013-08-16 2018-06-26 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
CA3175967A1 (en) 2013-09-13 2015-03-19 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
CA2939156A1 (en) 2014-02-07 2015-08-13 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
WO2015120270A1 (en) 2014-02-07 2015-08-13 Pioneer Hi Bred International, Inc. Insecticidal proteins and methods for their use
CA2960102C (en) * 2014-09-11 2023-10-24 Vlp Therapeutics, Llc Flavivirus virus like particle
CN113372421A (en) 2014-10-16 2021-09-10 先锋国际良种公司 Insecticidal proteins and methods of use thereof
CN107529763B (en) 2015-03-11 2021-08-20 先锋国际良种公司 Insecticidal combinations of PIP-72 and methods of use
CN116333064A (en) 2015-05-19 2023-06-27 先锋国际良种公司 Insecticidal proteins and methods of use thereof
US11198709B2 (en) 2015-08-06 2021-12-14 E. I. Du Pont De Nemours And Company Plant derived insecticidal proteins and methods for their use
EP3390431A1 (en) 2015-12-18 2018-10-24 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
MX2018013249A (en) 2016-05-04 2019-02-13 Pioneer Hi Bred Int Insecticidal proteins and methods for their use.
MX2018015540A (en) * 2016-06-20 2019-04-11 Janssen Vaccines & Prevention Bv Potent and balanced bidirectional promoter.
US11155829B2 (en) 2016-07-01 2021-10-26 Pioneer Hi-Bred International, Inc. Insecticidal proteins from plants and methods for their use
US11021716B2 (en) 2016-11-01 2021-06-01 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
CA3044404A1 (en) 2016-12-14 2018-06-21 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
WO2018118811A1 (en) 2016-12-22 2018-06-28 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
US20190390219A1 (en) 2017-02-08 2019-12-26 Pioneer Hi-Bred International, Inc. Insecticidal combinations of plant derived insecticidal proteins and methods for their use
CN110621780B (en) 2017-05-11 2024-03-19 先锋国际良种公司 Insecticidal proteins and methods of use thereof
WO2020198731A2 (en) 2019-03-28 2020-10-01 Danisco Us Inc Engineered antibodies
US20230235352A1 (en) 2020-07-14 2023-07-27 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995016027A1 (en) * 1993-12-06 1995-06-15 Bioinvent International Ab Method of selecting specific bacteriophages
WO1996011279A2 (en) * 1994-10-03 1996-04-18 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
WO1997007128A1 (en) * 1995-08-21 1997-02-27 Duke University A method to increase the density of antigen on antigen presenting cells
WO1997020078A1 (en) * 1995-11-30 1997-06-05 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
WO1997032987A1 (en) * 1996-03-08 1997-09-12 University Of Toronto Methods and nucleic immunogenic compositions encoding antigens and co-stimulatory molecules for immunization
WO1997035957A1 (en) * 1996-03-25 1997-10-02 Maxygen, Inc. Evolving cellular dna uptake by recursive sequence recombination

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882278A (en) * 1983-04-29 1989-11-21 President And Fellows Of Harvard College Non-toxinogenic vibrio cholerae mutants
IL96475A0 (en) * 1989-11-29 1991-08-16 Innovative Tech Center Chimeric proteins
JPH08510639A (en) * 1993-04-19 1996-11-12 メディソーブ・テクノロジーズ・インターナショナル・リミテッド・パートナーシップ Encapsulation of conjugates and nucleic acids for enhanced cellular uptake and gene expression and targeting
SG54115A1 (en) * 1993-04-27 1998-11-16 Gerber Scient Products Inc Thermal printing apparatus with improved power supply
WO1994026787A1 (en) * 1993-05-07 1994-11-24 The Board Of Trustees Of The Leland Stanford Junior University Method for generating cell type specific phage antibody libraries
WO1996013250A1 (en) * 1994-10-27 1996-05-09 Amgem Inc. Compositions for increased bioavailability of orally delivered therapeutic agents
AU716056B2 (en) * 1995-01-31 2000-02-17 Rockefeller University, The Identification of DEC, (dentritic and epithelial cells, 205 kDa), a receptor with C-type lectin domains, nucleic acids encoding DEC, and uses thereof
CZ92998A3 (en) * 1995-09-28 1998-09-16 University Of Pittsburgh Of The Commonwealth System Of Higher Education Process of stimulating cellularly mediated immunity response by making use of immunization through gene material bound on particles
US6489145B1 (en) * 1996-07-09 2002-12-03 Diversa Corporation Method of DNA shuffling

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995016027A1 (en) * 1993-12-06 1995-06-15 Bioinvent International Ab Method of selecting specific bacteriophages
WO1996011279A2 (en) * 1994-10-03 1996-04-18 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
WO1997007128A1 (en) * 1995-08-21 1997-02-27 Duke University A method to increase the density of antigen on antigen presenting cells
WO1997020078A1 (en) * 1995-11-30 1997-06-05 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
WO1997032987A1 (en) * 1996-03-08 1997-09-12 University Of Toronto Methods and nucleic immunogenic compositions encoding antigens and co-stimulatory molecules for immunization
WO1997035957A1 (en) * 1996-03-25 1997-10-02 Maxygen, Inc. Evolving cellular dna uptake by recursive sequence recombination

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
BENHAM A.M. & NEEFJES J.J.: "Proteasome activity limits the assembly f MHC class I molecules after IFN-gamma stimulation.", J. IMMUNOL., vol. 159, no. 2, 15 December 1997 (1997-12-15), pages 5896 - 5904, XP002117254 *
CONRY R M ET AL: "SELECTED STRATEGIES TO AUGMENT POLYNUCLEOTIDE IMMUNIZATION", GENE THERAPY, vol. 3, no. 1, 1 January 1996 (1996-01-01), pages 67 - 74, XP002035090, ISSN: 0969-7128 *
DAVIS H L ET AL: "DNA-based immunization against hepatitis B surface antigen (HBsAg) in normal and HBsAg-transgenic mice", VACCINE, vol. 15, no. 8, 1 June 1997 (1997-06-01), pages 849-852, XP004075668, ISSN: 0264-410X *
HOURVITZ A. ET AL.: "Reactogenicity and immunogenicity of a new recombinant hepatitis B vaccine containing Pre S antigens: a preliminary report", J. VIRAL HEPATITIS, vol. 3, 1996, pages 37 - 42, XP002117256 *
IRVINE K R ET AL: "CYTOKINE ENHANCEMENT OF DNA IMMUNIZATION LEADS TO EFFECTIVE TREATMENT OF ESTABLISHED PULMONARY METASTASES", JOURNAL OF IMMUNOLOGY, vol. 156, 1 January 1996 (1996-01-01), pages 238 - 245, XP002030631, ISSN: 0022-1767 *
KLINMAN D.M. ET AL.: "Contribution of CpG motifs to the immunogenicity of DNA vaccines", J. IMMUNOLOGY, vol. 158, 1997, pages 3635 - 3639, XP002108454 *
KRIEGER M ET AL: "MOLECULAR FLYPAPER, ATHEROSCLEROSIS, AND HOST DEFENSE: STRUCTURE AND FUNCTION OF THE MACROPHAGE SCAVENGER RECEPTOR", COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, vol. 57, 1 January 1992 (1992-01-01), pages 605 - 609, XP000561876 *
MARCO DI A ET AL: "AGONISTIC AND ANTAGONISTIC VARIANTS OF CILIARY NEUROTROPHIC FACTOR (CNTF) REVEAL FUNCTIONAL DIFFERENCES BETWEEN MEMBRANE-BOUND AND SOLUBLE CNTF ALPHA-RECEPTOR", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 37, 12 September 1997 (1997-09-12), pages 23069 - 23075, XP002069814, ISSN: 0021-9258 *
PATTEN P A ET AL: "APPLICATIONS OF DNA SHUFFLING TO PHARMACEUTICALS AND VACCINES", CURRENT OPINION IN BIOTECHNOLOGY, vol. 8, 1997, pages 724 - 733, XP002916609, ISSN: 0958-1669 *
SAGGIO I ET AL: "CNTF VARIANTS WITH INCREASED BIOLOGICAL POTENCY AND RECEPTOR SELECTIVITY DEFINE A FUNCTIONAL SITE OF RECEPTOR INTERACTION", EMBO JOURNAL, vol. 14, no. 13, 1 January 1995 (1995-01-01), pages 3045 - 3054, XP002056939, ISSN: 0261-4189 *
SHEU S.Y. & LO S.J.: "Deletion or alteration of hydrophobic amino acids at the third transmembrane domains of Hepatitis B surface antigen enhances its production in Escherichia coli.", GENE, vol. 160, no. 2, 28 July 1995 (1995-07-28), pages 179 - 184, XP002117290 *
SHOUVAL D. ET AL.: "Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines", VACCINE, vol. 12, no. 15, November 1994 (1994-11-01), pages 1453 - 1459, XP002117255 *
XIANG Z ET AL: "MANIPULATION OF THE IMMUNE RESP0NSE TO A PLASMID-ENCODED VIRAL ANTIGEN BY COINOCULATION WITH PLASMIDS EXPRESSING CYTOKINES", IMMUNITY, vol. 2, no. 2, 1 February 1995 (1995-02-01), pages 129 - 135, XP000670098, ISSN: 1074-7613 *
ZOU J.J. ET AL.: "Structure-function analysis of the p35 subunit of mouse interleukin 12", J. BIOL.CHEM., vol. 270, no. 11, 17 March 1995 (1995-03-17), pages 5864 - 5871, XP002117289 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821957B2 (en) 1997-05-20 2004-11-23 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
US9512382B2 (en) 2009-10-16 2016-12-06 Bunge Global Innovation, Llc Oil degumming methods

Also Published As

Publication number Publication date
WO1999041402A3 (en) 1999-11-11
JP2002503478A (en) 2002-02-05
CA2320960A1 (en) 1999-08-19
JP2002503461A (en) 2002-02-05
WO1999041369A3 (en) 1999-09-23
MXPA00007889A (en) 2002-09-18
CA2320626A1 (en) 1999-08-19
WO1999041368A2 (en) 1999-08-19
MXPA00007893A (en) 2002-10-23
AU2674199A (en) 1999-08-30
EP1056842A2 (en) 2000-12-06
EP1053343A2 (en) 2000-11-22
AU2674299A (en) 1999-08-30
JP2002507392A (en) 2002-03-12
WO1999041402A2 (en) 1999-08-19
WO1999041369A2 (en) 1999-08-19
MXPA00007891A (en) 2002-09-18
EP1053312A2 (en) 2000-11-22
AU3291099A (en) 1999-08-30
CA2320431A1 (en) 1999-08-19

Similar Documents

Publication Publication Date Title
WO1999041368A3 (en) Optimization of immunomodulatory properties of genetic vaccines
WO2004075829A3 (en) Adjuvanted influenza vaccine
WO2000002522A3 (en) Anthrax vaccine
WO2003059381A3 (en) Immunogenic preparations and vaccines on the basis of mrna
MY125202A (en) Vaccine
WO2004006837A3 (en) Mesothelin vaccines and model systems
EP1032417A4 (en) Bacterial vaccines comprising auxotrophic, attenuated strains of listeria expressing heterologous antigens
AU2002355677A1 (en) Antigenic polypeptides
WO2001034801A3 (en) Recombinant gelatin in vaccines
DE69929444D1 (en) CPG COMPOSITIONS, SAPONIN ADJUVANTIES, AND METHOD OF USE THEREOF
WO1999036544A3 (en) Neisseria meningitidis antigens
EP1203817A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
DE60335010D1 (en) IMMUNOSTIMULATORY COMPOSITIONS AND METHOD FOR STIMULATING AN IMMUNE RESPONSE
NO20001768D0 (en) Virus encapsulation vaccine, method of preparation and use thereof
AU2002365508A1 (en) Apparatus and method for modification of magnetically immobilized biomolecules
WO2003051392A3 (en) Streptococcus pneumoniae vaccine
WO2004062597A3 (en) Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector
WO1999042076A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
CY1107950T1 (en) NAVIGATION VACCINE COMPOSITIONS AND METHODS
EP1364037A4 (en) Methods and compositions useful for stimulating an immune response
WO2004005476A3 (en) Nucleic acid compositions for stimulating immune responses
WO2002024739A3 (en) Spas-1 cancer antigen
WO2003051288A3 (en) Mycobacterial vaccine
HK1056292A1 (en) Method of culturing zooplankton, apparatus for culturing by the same, and culture obtained by the same.
IL154776A0 (en) Method for the preparation of 21-hydroxy-6, 19-oxidoprogesterone and derivatives thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2320960

Country of ref document: CA

Ref country code: CA

Ref document number: 2320960

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 2000 531549

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/007889

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 26741/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999906948

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999906948

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999906948

Country of ref document: EP